American Home Products Corporation

Other

Paul P Hung

Narender K Kalyan

Shaw-Guang L Lee

Alan R Davis

Shawguang L Lee

Michael D Lubeck

Robert J Natuk

Pranab K Chanda

Shridhara C S Murthy

This invention provides a method of protecting a primate from an infectious organism by stimulating the production of antibodies or cell mediated immunity to the infectious organism which comprises administering to said primate intranasally, intramuscularly, or subcutaneously, live recombinant adenoviruses in which the virion structural protein is unchanged from that in the native adenovirus from which the recombinant adenovirus is produced, and which contain the gene coding for the antigen corresponding to said antibodies or inducing said cell mediated immunity. Preferably, the infectious organism is HIV and the primate is a human.

Methods for producing an immune response against HIV-1

Methods and vaccines for the production of antibodies to infectious organisms are described. Live recombinant adenovirus containing a foreign gene coding for an antigen produced by another infectious organism is delivered to the intestine of a warm-blooded animal in an enteric-coated dosage form, whereupon the virus infects the gut wall and induces the production of antibodies or cell mediated immunity to both adenovirus and the other infectious organism.

Oral vaccines

Chimeric DNA fragments are provided which include a nucleotide sequence substantially the same as that which codes for the HA surface protein of an influenza A virus having five immunodominant antigenic sites, wherein a nucleotide sequence substantially the same as that which codes for a foreign epitope is inserted into the nucleotide sequence of an antigenic site. Corresponding chimeric peptides, expression vectors, and transformed hosts are provided as well. These peptides are useful in providing vaccines against the respective antigens and in test kits to detect the exposure to such antigens. Additionally, these peptides or their corresponding antibodies are useful in methods of treatment and prevention of the manifestations of exposure to these antigens, including immunotherapy.

Expression of specific immunogens using viral antigens

Des-epidermal growth factor homologous--plasminogen activators with greatly diminished affinity for liver membranes.

Des-epidermal growth factor plasminogen activators

Tris-Kringle plasminogen activators containing an additional second kringle domain or an additional modified second kringle domain are useful in disrupting blood clots.

Tris-Kringle plasminogen activator with novel K2 insert

Hybrid, third generation, plasminogen activators containing plural, heterologous polypeptide kringles prepared by recombinant DNA techniques as well as the genes coding for the activators, Vectors containing those genes and a method for using the plasminogen activators as thrombolytic agents, are disclosed.

Process for treating thrombosis by administering poly-kringle

Hybrid, third generation, plasminogen activators containing plural, heterologous polypeptide kringles prepared by recombinant DNA techniques as well as the genes coding for the activators. Vectors containing those genes and a method for using the plasminogen activators as thrombolytic agents, are disclosed.

Poly-kringle plasminogen activator

The invention disclosed herein provides a method of treating an animal infected by hepatitis B virus comprising administering to such infected animal an amount of a rifamycin derivative selected from a group consisting of

Growing community of inventors

Bryn Mawr, PA, United States of America

Paul P Hung